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The effects of vasopressin and related peptides upon the rat skeletal muscle cell line, L6, have been exam- 
ined. No effects upon cellular cyclic AMP levels were found indicating that L6 cells possess no functional 
V,-vasopressin receptors. Vasopressin and its analogues did, however, stimulate the rapid and dose-depen- 
dent accumulation of inositol phosphates. This effect and the rank order of potency of vasopressin analo- 
gues demonstrate the presence of functional V,-vasopressin receptors upon L6 cells. These results suggest 
that the L6 line may be a useful model for vasopressin effects upon skeletal muscle metabolism. 
Vasopressin; V, receptor; Inositol phosphate; (L6 skeletal muscle cell) 
1. INTRODUCTION 
Vasopressin has actions both as a hormone 
(anti-diuretic hormone) and as a neural peptide 
transmitter in various tissues. It appears to act 
through two distinct types of receptors which have 
been termed V1 and VZ receptors, both of which 
are coupled to distinct second messenger genera- 
tion systems [I]. Vi receptors are coupled to the 
stimulation of inositol phospholipid breakdown 
whereas VZ receptor occupancy leads to the 
stimulation of adenylate cyclase activity. 
From in vivo studies with various rat skeletal 
muscle preparations [2] and in vitro studies using 
chick embryonic skeletal muscle cells in culture [3] 
it has been proposed that vasopressin triggers the 
breakdown of muscle glycogen by a mechanism in- 
volving the activation of glycogen phosphorylase, 
the activity of this enzyme apparently being 
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augmented by two distinct pathways, namely by an 
increase in either intracellular free Ca2+ or cyclic 
AMP concentrations. 
In hepatocytes, vasopressin activates glycogen 
phosphorylase in a Ca2+-dependent, cyclic AMP- 
independent manner [4]. This effect of the peptide 
upon Ca2+ levels is, however, secondary to the 
stimulated breakdown of phosphatidylinositol 
4,Sbisphosphate and the consequent production 
of the two second messengers, inositol 
1,4,Strisphosphate and 1 ,Zdiacylglycerol (reviews 
[5,6]). The mechanism whereby vasopressin acts 
upon muscle tissue is, however, unknown and 
there are no reports in the literature as to ligand- 
stimulated effects upon inositol phospholipid 
metabolism in skeletal as opposed to smooth mus- 
cle cells. 
Accordingly, we have examined the effects of 
vasopressin upon the L6 skeletal muscle line in 
order to investigate the presence and 
characteristics of vasopressin receptors on a dif- 
ferentiated cell line model of skeletal muscle. Here, 
we show that the L6 skeletal muscle line possesses 
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a functional vasopressin VI-receptor which is 
coupled to the stimulation of inositol phospholipid 
breakdown. 
2. MATERIALS AND METHODS 
L6 cells, purchased from the American Type 
Culture Collection, were cultured in 10 cm 
diameter plastic tissue culture dishes in Dulbecco’s 
modified Eagle’s medium containing 10% (v/v) 
heat-inactivated foetal calf serum and 100 @g/ml 
gentamycin. The cells were maintained at 95% 
humidity at 37°C in an atmosphere of 92% air, 8% 
COZ. 48 h before experiments were performed the 
medium was changed to one containing 1 &i/ml 
myo-[2-3H]inositol (NEN). Cells were 75-80% 
confluent when used for experiments. 
On the day of experiments the medium was 
removed from the dishes and the monolayers 
washed with Hank’s buffered saline containing 1% 
(w/v) bovine serum albumin and 10 mM glucose 
(HBG). The cells were then scraped from the 
dishes using a teflon-coated spatula, washed in 
HBG and resuspended in HBG containing 10 mM 
LiCl. The cell suspension (0.24 ml, 2 x lo6 
cells/ml) was dispensed into plastic biovials con- 
taining 10 ~1 of test substance or buffer. The vials 
were gassed (95% 02: 5% COZ) capped and in- 
cubated in a shaking water bath at 37°C for 
45 min. Incubations were terminated by the addi- 
tion of 0.94 ml chloroform/methanol (1: 2) and 
the phases split by the addition of 0.31 ml each of 
chloroform and water. Radioactivity associated 
with the total inositol phosphates in an aliquot of 
the aqueous layer was determined by liquid scin- 
tillation counting following batch chromatography 
on Dowex 1 x 8 formate resins as in [7]. The 
radioactivity in the lipids was determined upon a 
dried aliquot of the lower, organic phase. 
Cyclic AMP was determined in cells by use of a 
binding protein assay [8]. Experiments were per- 
formed using cells grown on 35 mm diameter 
dishes. The growth medium was aspirated and 
replaced with HBG and the cells allowed to in- 
cubate for 45 min. IBMX was then added to a final 
concentration of 1 mM. After 15 min stimulants 
were added as described in section 3. Incubations 
were terminated by the addition of 0.5 ml ice-cold 
5% perchloric acid and the cyclic AMP concentra- 
tions determined as described in [8]. 
182 
3. RESULTS AND DISCUSSION 
Table 1 shows that [3H]inositol-labelled 
phosphates were generated in L6 muscle cells upon 
stimulation by the addition of vasopressin. This ef- 
fect was observed in response to arginine- 
vasopressin, lysine-vasopressin, vasotocin and ox- 
ytocin, but not in response to mesotocin or 
pressinoic acid. Table 1 also shows that arginine- 
vasopressin did not stimulate the production of 
inositol phosphates in the presence of the 
vasopressin receptor antagonist, l-@mercapto- 
P,&cyclopentamethylenepropionic a id)-2-(O-meth- 
yl)tyrosine]-8-arginine-vasopressin. The effects of 
vasopressin upon inositol phospholipid meta- 
bolism can therefore be concluded to be receptor 
mediated. 
Stimulation of L6 cells with arginine-vasopressin 
had no effect upon the intracellular concentration 
of cyclic AMP. Stimulation of the cells with 
adrenaline, however, caused a greater than 
lOOO-fold increase in cyclic AMP levels (not 
shown). This result confirms previous observations 
Table 1 
The effect of vasopressin and analogues upon inositol 
phosphate generation i  L6 cells 
Agonist 
None 
Lysine-vasopressin 
Arginine-vasopressin 
Vasotocin 
Mesotocin 
Oxytocin 
Pressinoic acid 
Arginine-vasopressin + 
cpm in Fold 
inositol increase over 
phosphates control 
308 f 34 - 
1447 f 124 4.7 + 0.5 
1210 + 124 3.9 f 0.6 
1327 + 73 4.3 ? 0.4 
354 f 64 1.2 f 0.4 
527k 38 1.7+0.2 
274 + 37 0.9 + 0.1 
antagonist 275 + 15 0.9 + 0.1 
L6 cells were incubated and labelled as described in 
section 2. The cells were washed, incubated with agonists 
for 45 min in the presence of 10 mM LiCl and the 
radioactivity in inositol phosphates determined as 
described in section 2. Results are means f SD from one 
experiment typical of two; n = 3 in each case. 
Concentrations in each case are 40pM except for 
arginine vasopressin which is 4rM, or 400 nM when 
tested against the antagonist 
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Fig. 1. Dose-response curves for the effects of various vasopressin analogues upon inositol phosphate generation in L6 
cells. Experiments were performed as described in the legend to table 1 and section 2. The results are expressed as 
means f SD of the fold increase in cpm in the inositol phosphates compared to control values. Typically control inositol 
phosphates were 150-300 cpm and the control lipids 3000-5000 cpm. The data are pooled from 12 separate experiments 
and n = 6-24. A, arginine-vasopressin; B, lysine-vasopressin; C, vasotocin; D, oxytocin. 
which demonstrated functional ,&adrenergic recep- 
tors in L6 skeletal muscle cells [9]. 
Since V1 receptors have been shown to be cou- 
pled to stimulated inositol phospholipid break- 
down and VZ receptors to the stimulation of 
adenylate cyclase activity in a variety of tissues (see 
[4] and references therein) it is clear that L6 
skeletal muscle cells possess functional Vi-vaso- 
pressin receptors coupled to stimulated inositol 
phospholipid metabolism. The nature of this 
vasopressin receptor is confirmed by the rank 
order of potency obtained from the results 
presented in fig. 1. Thus, arginine-vasopressin = 
lysine-vasopressin > vasotocin > oxytocin 4 
mesotocin = presinoic acid, the last two peptides 
being inactive. In addition the EDso for arginine- 
vasopressin of 10 nM (fig.lA) compares well with 
published values of 5 and 21 nM for vasopressin- 
stimulated inositol phosphate production [lo] and 
inositol phospholipid breakdown [ 111, respective- 
ly, in isolated hepatocytes. An identical EDso value 
to that of arginine-vasopressin was found for 
lysine-vasopressin (fig. 1B). Vasotocin (fig. 1C) has 
an EDso of 20 nM whereas that for oxytocin was 
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found to be 200 nM (fig.lD). An identical rank 
order of potency was found in isolated 
hepatocytes, a Vi-vasopressin receptor containing 
cell, by Kirk et al. [4]. 
The rank order of potency demonstrates that for 
stimulation of inositol phospholipid breakdown a 
basic amino acid is required at position 8 of the 
agonist peptide. The discrimination between ox- 
ytocin and mesotocin is surprising in that these two 
peptides differ only at position 8, where oxytocin 
has a leucine and mesotocin an isoleucine residue. 
This result strongly suggests a precise spatial re- 
quirement for the side chain in position 8 in that 
isoleucine differs from the acceptable substitu- 
tions, lysine, arginine and leucine, in having a 
methyl group on the a-carbon position. 
It has been proposed previously that vasopressin 
exerts effects upon skeletal muscle glycogen 
metabolism [2,3]. The results presented here imply 
that such a function is mediated by stimulation of 
inositol phospholipid metabolism by functional 
Vr-vasopressin receptors. Since the primary regula- 
tion of skeletal muscle metabolism and function is 
neuronal, it is probable that any physiological 
regulation of glycogen metabolism by vasopressin 
is also of neuronal origin and may be related to the 
occurrence of a vasopressin-like peptide (VLP) in 
peripheral nerves [12]. Indeed, VLP has been sug- 
gested to be active preferentially at Vr receptors. 
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